Schroder Investment Management Group Has $36.73 Million Position in USANA Health Sciences, Inc. (USNA)
Schroder Investment Management Group increased its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 9.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 572,186 shares of the company’s stock after purchasing an additional 47,448 shares during the quarter. Schroder Investment Management Group owned approximately 2.29% of USANA Health Sciences worth $36,734,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its position in USANA Health Sciences by 13.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock worth $135,000 after acquiring an additional 245 shares during the period. Victory Capital Management Inc. boosted its position in USANA Health Sciences by 124.7% during the 1st quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock worth $122,000 after acquiring an additional 1,175 shares during the period. Creative Planning boosted its position in USANA Health Sciences by 528.0% during the 2nd quarter. Creative Planning now owns 2,512 shares of the company’s stock worth $161,000 after acquiring an additional 2,112 shares during the period. SG Americas Securities LLC acquired a new stake in USANA Health Sciences during the 2nd quarter worth about $162,000. Finally, Eqis Capital Management Inc. acquired a new stake in USANA Health Sciences during the 2nd quarter worth about $210,000. 44.90% of the stock is currently owned by hedge funds and other institutional investors.
In other USANA Health Sciences news, insider Daniel A. Macuga sold 5,751 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $60.00, for a total value of $345,060.00. Following the completion of the sale, the insider now directly owns 2,077 shares in the company, valued at $124,620. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel A. Macuga sold 11,992 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $59.00, for a total value of $707,528.00. Following the completion of the sale, the insider now owns 11,992 shares of the company’s stock, valued at $707,528. The disclosure for this sale can be found here. Insiders sold 244,032 shares of company stock valued at $14,352,462 over the last 90 days. Corporate insiders own 53.20% of the company’s stock.
Shares of USANA Health Sciences, Inc. (USNA) opened at 57.90 on Monday. The firm’s 50-day moving average price is $58.13 and its 200-day moving average price is $60.22. USANA Health Sciences, Inc. has a 12 month low of $52.55 and a 12 month high of $75.00. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 15.04 and a beta of 1.10.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The business had revenue of $257.10 million during the quarter, compared to the consensus estimate of $273.61 million. During the same quarter last year, the company earned $2.07 earnings per share. The firm’s revenue was down .5% compared to the same quarter last year. On average, equities analysts anticipate that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.
USANA Health Sciences declared that its board has authorized a stock repurchase program on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to repurchase up to 46% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.
A number of equities research analysts have commented on the company. BidaskClub lowered USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Pivotal Research decreased their price objective on USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, July 26th.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.